Skip to main content

Journal for Biophysical Chemistry

Table 1 Functional targeting of the HCV replicase

From: Model Membrane Platforms for Biomedicine: Case Study on Antiviral Drug Development

Protein

Membrane associating region

Replicase function(s)

Functional targets

Necessary for replication

Drug pipeline

NS2

At least one transmembrane domain

(1) NS2–NS3 proteolytic cleavage

(1) Transmembrane domains

Noa

Preclinical

(2) Protease active site

(3) Dimerization motif

NS3

None

(1) Serine protease domain releases NS proteins downstream

(1) Protease active site

Yes

Phase lll/IVb

(2) Helicase active site

(2) Helicase domain unwinds dsRNA/ssRNA

(3) NTPase active site

(4) RNA-binding region

(5) NS4A- and NS5B-interaction regions

NS4A

N-terminal transmembrane domain

(1) NS3 cofactor for proper folding and membrane localization

(1) N-terminal transmembrane domain

Yes

ibid

NS4B

N-terminal AH

(1) Induces membranous web formation

(1) N-terminal AH

Yes

Phase I

(2) Internal AH

(3) RNA-binding region

(4) Oligomerization motif

NS5A

N-terminal AH

Unknownc

(1) N-terminal AH

Yes

Phase Id

(2) Domain I dimerization motif for RNA binding

(3) Core protein interaction region

NS5B

C-terminal anchor region

(1) Synthesis of viral genome RNA

(1) Polymerase active site

Yes

Phase II

(2) Allosteric binding sites

(3) NS3- and NS5A-interaction regions

(4) RNA-binding region

(5) Oligomerization motif

  1. Like other positive-strand RNA viruses, HCV genome replication occurs in intimate association with host cell or host cell-derived intracellular membranes. HCV NS proteins play critical roles in the replication process, and are responsible for replicase assembly and function, including synthesis of the viral genome. Targeting critical functions of NS proteins is an attractive pharmaceutical strategy to halt HCV infection. A summary of NS proteins including their membrane-associating domain, function, necessity for viral replication and status as a drug target is presented. Information presented in the table was collected from Refs. [50, 51, 53, 58, 119]
  2. aProteolytic cleavage of the NS2–NS3 polyprotein is necessary prior to replication
  3. bClinical stage NS3/NS4A drug candidates exclusively target protease activity
  4. cNSSA phosphorylation is proposed to regulate the switch between HCV genome replication and virion assembly
  5. dBMS-790052 has a picomolar EC50. High therapeutic index and synergetic cocktail effects in Vitro